Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
O60462

UPID:
NRP2_HUMAN

ALTERNATIVE NAMES:
Vascular endothelial cell growth factor 165 receptor 2

ALTERNATIVE UPACC:
O60462; A0A024R3W6; A0A024R412; E9PF66; O14820; O14821; Q53TQ4; Q53TS3; Q7LBX6; Q7LBX7; Q9H2D4; Q9H2D5; Q9H2E2; Q9H2E3; Q9H2E4; X5D2Q8

BACKGROUND:
Neuropilin-2 serves as a critical receptor for various growth factors, including semaphorins 3C, 3F, and specific isoforms of VEGF and PGF, highlighting its importance in vascular biology and neuronal guidance. It also facilitates the entry of human cytomegalovirus in certain cells, indicating its role in microbial infection.

THERAPEUTIC SIGNIFICANCE:
The exploration of Neuropilin-2's functions offers a pathway to innovative therapeutic approaches. Given its pivotal role in both physiological processes and disease mechanisms, targeting Neuropilin-2 could lead to breakthroughs in treating vascular diseases and viral infections.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.